ATC Abstracts

American Transplant Congress abstracts

2018 American Transplant Congress » Concurrent Session: Kidney Immunosuppression: mTORi Based Regimens

Date: Sunday, June 3, 2018

Time: 2:30pm-4:00pm

Location: Room 6A

Session Type: Concurrent Session

Meeting: 2018 American Transplant Congress

2:30pm-2:42pm
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study

F. Oppenheimer,1 C. Legendre,1 J. Cruzado,1 G. Russ,1 O. Viklicky,1 R. Oberbauer,1 V. Garcia,1 O. Witzke,1 D. Kuypers,1 R. Danguilan,1 P. Bernhardt,2 C. Sommerer.1

2:42pm-2:54pm
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients

F. Vincenti, J. Cruzado, S. Mulgaonkar, V. Garcia, D. Kuypers, M. Buchler, F. Citterio, U. Huynh-Do, W-.L. Luo, P. Bernhardt, C. Sommerer.

2:54pm-3:06pm
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study

S. Mulgaonkar,1 Y. Qazi,1 D. Kim,1 V. Peddi,1 K. McCague,2 D. Patel,2 A. Wiseman.1

3:06pm-3:18pm
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies

F. Shihab,1 Y. Qazi,1,2 V. Peddi,1 D. Shaffer,1 D. Kim,1,2 K. McCague,3 D. Patel,3 S. Mulgaonkar.1,2

3:18pm-3:30pm
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients

B. Suwelack,1 C. Sommerer,1 D. Dragun,1 O. Witzke,1 C. Hugo,1 N. Kamar,2 P. Merville,2 A. Hauser,1 P. Schenker,1 M. Junge,3 B. Nashan,1 F. Thaiss.1

3:30pm-3:42pm
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study

B. Nashan,1 C. Sommerer,1 B. Suwelack,1 D. Dragun,1 O. Witzke,1 C. Hugo,1 N. Kamar,2 P. Merville,2 A. Hauser,1 P. Schenker,1 M. Junge,3 F. Thaiss.1

3:42pm-3:54pm
Investigation of Lower Treatment Failure Rate Seen among Black Kidney Recipients on LCP-Tacrolimus vs. IR-Tacrolimus: Subgroup Analyses of Two Phase 3 Trials

T. Sparkes,1 B. Masters,1 C. Staino,2 S. Patel,2 M. Cooper.3

« View all sessions from the 2018 American Transplant Congress